[go: up one dir, main page]

IL177007A0 - 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors - Google Patents

2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors

Info

Publication number
IL177007A0
IL177007A0 IL177007A IL17700706A IL177007A0 IL 177007 A0 IL177007 A0 IL 177007A0 IL 177007 A IL177007 A IL 177007A IL 17700706 A IL17700706 A IL 17700706A IL 177007 A0 IL177007 A0 IL 177007A0
Authority
IL
Israel
Prior art keywords
thiazoles
aryl
amino
substituted
tyrosine kinase
Prior art date
Application number
IL177007A
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of IL177007A0 publication Critical patent/IL177007A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
IL177007A 2004-01-30 2006-07-20 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors IL177007A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54006404P 2004-01-30 2004-01-30
PCT/IB2005/000401 WO2005073225A1 (en) 2004-01-30 2005-01-28 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IL177007A0 true IL177007A0 (en) 2006-12-10

Family

ID=34826177

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177007A IL177007A0 (en) 2004-01-30 2006-07-20 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors

Country Status (12)

Country Link
EP (1) EP1711497A1 (en)
JP (1) JP2007519711A (en)
KR (1) KR20060129413A (en)
CN (1) CN1934107A (en)
AU (1) AU2005209485A1 (en)
BR (1) BRPI0507271A (en)
CA (1) CA2554925A1 (en)
IL (1) IL177007A0 (en)
NO (1) NO20063861L (en)
NZ (1) NZ548884A (en)
WO (1) WO2005073225A1 (en)
ZA (1) ZA200606152B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101610768B (en) * 2006-04-20 2012-03-21 詹森药业有限公司 Methods of inhibiting C KIT kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5089681B2 (en) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Heterocyclic compounds as inhibitors of c-fms kinase
CA2650057C (en) 2006-04-20 2014-07-29 Janssen Pharmaceutica N.V. Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CN101801964A (en) 2007-05-22 2010-08-11 艾其林医药公司 Heteroaryl substituted thiazoles and their use as antiviral agents
JO3240B1 (en) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
ES2528032T3 (en) 2009-01-16 2015-02-03 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy to prevent, treat or manage metastatic cancer
WO2013014170A1 (en) * 2011-07-27 2013-01-31 Ab Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)
CN103130792B (en) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 A kind of thiazolamine compounds
US9290489B2 (en) 2012-07-06 2016-03-22 Duke University Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CN103254184B (en) * 2013-05-27 2015-03-18 湖南科技大学 5-substituted-3-[5-hydroxy-4-pyrone-2-yl-methylmercapto]-4-amino-1,2,4-triazole compound and application thereof
CN103319467B (en) * 2013-06-15 2015-10-14 湖南科技大学 A kind of 4-[5-hydroxyl-pyrokomane-2-base methylene is amino]-3-sulfydryl-1,2,4-triazole compounds and purposes
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CN109310683A (en) 2016-04-07 2019-02-05 杜克大学 Small molecule dual inhibitor of TRPV4 and TRPA1 for disinfection and anesthesia
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (en) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) A method of treating cancer that has acquired resistance to a kinase inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20032896B (en) * 1997-10-27 2003-02-25 Agouron Pharma 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
BR0009721A (en) * 1999-04-15 2002-02-13 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
HN2002000156A (en) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
KR100979988B1 (en) * 2001-08-13 2010-09-03 얀센 파마슈티카 엔.브이. 2-amino-4,5-trisubstituted thiazolyl derivatives
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
NZ538490A (en) * 2002-08-02 2006-12-22 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-kit inhibitors
MXPA05013075A (en) * 2003-06-03 2006-03-17 Novartis Ag P-38 inhibitors.

Also Published As

Publication number Publication date
CN1934107A (en) 2007-03-21
AU2005209485A1 (en) 2005-08-11
ZA200606152B (en) 2007-11-28
EP1711497A1 (en) 2006-10-18
NZ548884A (en) 2010-06-25
BRPI0507271A (en) 2007-06-26
WO2005073225A1 (en) 2005-08-11
CA2554925A1 (en) 2005-08-11
NO20063861L (en) 2006-10-23
KR20060129413A (en) 2006-12-15
JP2007519711A (en) 2007-07-19

Similar Documents

Publication Publication Date Title
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
EP1794137A4 (en) Specific kinase inhibitors
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL183276A0 (en) Kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
IL181169A0 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
EP1954277A4 (en) Aminopyrimidines useful as kinase inhibitors
EP1581539A4 (en) Novel tyrosine kinase inhibitors
IL196337A0 (en) Tyrosine kinase inhibitors
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
SI1943243T1 (en) Kinase inhibitors
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
ZA200607648B (en) Kinase inhibitors
EP1778693A4 (en) Tricyclic-heteroaryl compounds useful as kinase inhibitors
EP1713793A4 (en) Pyrimidinone compounds useful as kinase inhibitors
ZA200608775B (en) Monocyclic heterocycles as kinase inhibitors
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
EP1651209A4 (en) TYROSINE KINASE INHIBITORS
ZA200804768B (en) Aminopyrimidines useful as kinase inhibitors